Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWJXFO)

• Drug Name: Mezagitamab Drug Info
• Synonyms: TAK-079

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Phase 2	[1]
Primary immune thrombocytopenia	3B64.10	Phase 2	[2]
IgA nephropathy	MF8Y	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMWJXFO

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclic ADP-ribose hydrolase 1 (CD38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daratumumab	DMKCIUZ	Multiple myeloma	2A83	Approved	[5]
CD38 and BCMA CAR-T Cells	DMFZS8A	Multiple myeloma	2A83	Phase 1/2	[6]
4SCAR19 and 4SCAR38	DMZKFU7	B-cell lymphoma	2A86	Phase 1/2	[7]
ISB 1342	DMG107N	Multiple myeloma	2A83	Phase 1/2	[8]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[9]
CD38 CAR T cells	DMPS3I6	Multiple myeloma	2A83	Phase 1/2	[10]
CD38 CAR-T Cell	DM0USBX	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[11]
SAR-650984	DMD20YH	Haematological malignancy	2B33.Y	Phase 1/2	[12]
MOR-202	DMR8AHJ	Multiple myeloma	2A83	Phase 1/2	[13]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	Not Available	[4]

References

• [1] ClinicalTrials.gov (NCT04159805) A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04278924) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05174221) A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy. U.S.National Institutes of Health.
• [4] Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
• [5] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
• [6] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [7] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [8] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [9] ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
• [10] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [11] ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
• [12] Clinical pipeline report, company report or official report of Sanofi-Aventis.
• [13] Clinical pipeline report, company report or official report of MorphoSys.
• [14] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies